Evidence map›Paper›PMID 36973294›Full record

ArticleNature communications2023

Neuraminidase 1 promotes renal fibrosis development in male mice.

Qian-Qian Chen, Kang Liu, Ning Shi, Gaoxiang Ma, Peipei Wang, Hua-Mei Xie, Si-Jia Jin, Ting-Ting Wei, Xiang-Yu Yu, Yi Wang and 4 more

Open access · goldFull text read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Regulation of calcium homeostasis by S100A12 drives NETosis in chronic kidney disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Advances in the Targeted Drug Delivery System for Renal Fibrosis.International journal of nanomedicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Qian-Qian Chen *State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Kang Liu *Department of Nephrology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Ning Shi *School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Gaoxiang MaClinical Metabolomics Center, China Pharmaceutical University, Nanjing, 211198, China.ORCID 0000-0002-1774-6445
Peipei WangCollege of Food Science and Technology, Shanghai Ocean University, Shanghai, 201306, China.
Hua-Mei XieClinical Metabolomics Center, China Pharmaceutical University, Nanjing, 211198, China.
Si-Jia JinSchool of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Ting-Ting WeiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Xiang-Yu YuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Yi WangClinical Metabolomics Center, China Pharmaceutical University, Nanjing, 211198, China.
Jun-Yuan ZhangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Ping LiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Lian-Wen QiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. Qilw@cpu.edu.cn.ORCID 0000-0003-0728-4475
Lei ZhangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. Zhanglei@cpu.edu.cn.
China Pharmaceutical University · CNJiangsu Province Hospital · CNNanjing University of Chinese Medicine · CNShanghai Ocean University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The functions of the influenza virus neuraminidase has been well documented but those of the mammalian neuraminidases remain less explored. Here, we characterize the role of neuraminidase 1 (NEU1) in unilateral ureteral obstruction (UUO) and folic acid (FA)-induced renal fibrosis mouse models. We find that NEU1 is significantly upregulated in the fibrotic kidneys of patients and mice. Functionally, tubular epithelial cell-specific NEU1 knockout inhibits epithelial-to-mesenchymal transition, inflammatory cytokines production, and collagen deposition in mice. Conversely, NEU1 overexpression exacerbates progressive renal fibrosis. Mechanistically, NEU1 interacts with TGFβ type I receptor ALK5 at the 160-200aa region and stabilizes ALK5 leading to SMAD2/3 activation. Salvianolic acid B, a component of Salvia miltiorrhiza, is found to strongly bind to NEU1 and effectively protect mice from renal fibrosis in a NEU1-dependent manner. Collectively, this study characterizes a promotor role for NEU1 in renal fibrosis and suggests a potential avenue of targeting NEU1 to treat kidney diseases.

Indexed as

Kidney DiseasesNeuraminidaseUreteral ObstructionAnimalsFibrosisGene ExpressionKidneyMaleMiceMice, Inbred C57BLNeu1 protein, mouseNeuraminidase

Identifiers

PMID36973294
PMCPMC10043283
OpenAlexW4360997904

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read110
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.